Session Abstract – PMWC 2023 Silicon Valley

Showcase Track S1 - January 25 11.00 A.M.-1.15 P.M.,Showcase Track S1 - January 26 11.30 A.M.-4.45 P.M.,Showcase Track S1 - January 27 10.15 A.M.-1.15 P.M.


The PMWC 2023 AI Company Showcase will provide a 15-minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.


Confirmed Presenting Companies:

 Speaker Profile

M.D., Technical Product Marketing Manager, Pachyderm

Biography
Bhavani Rao is currently a Technical Product Marketing Manager, responsible for product messaging and positioning at Pachyderm, a leader in data pipelining and MLOps. He has a diverse background, working with customers in Data Ops, DevOps, CI/CD, relational and NoSQL databases. A recent convert to the potential of AI/ML, Bhavani is passionate about technology and how it can be leveraged to solve customer problems. Throughout his career, Bhavani has promoted these learnings and best practices at numerous industry gatherings. He has a B.S. degree in Operations Research from Indiana University and an MBA from Columbia University.


AI and Data Sciences Showcase:
Pachyderm

Pachyderm enables data engineering teams to automate complex pipelines.

Applying ML: Processing Radiology Images at Scale
This session will discuss how to apply Deep Learning concepts to process petabytes of radiology images.

 Speaker Profile

PHD, CEO and Co-Founder, Healx

Biography
Tim is a tech entrepreneur from the Cambridge Cluster, passionate about using AI to accelerate treatments for rare diseases. He is Co-Founder and Chief Executive of Healx, the mission-driven technology company pioneering the next wave of drug discovery in order to bring novel, effective treatments to rare disease patients around the world. In this role, Tim has been listed in The Sunday Times Maserati 100 list in 2019, was featured in The Telegraph’s Tech 100 in 2019, and was named as ‘One to watch’ in The Telegraph’s Top 50 Most Ambitious Business Leaders in 2020. Tim is also the Co-Founder and Trustee of the Cambridge Rare Disease Network (CRDN). Prior to Healx and CRDN, he obtained his PhD at the University of Cambridge in the field of Biophysics and Neuroscience, developing nanobody technology for Parkinson's disease.


AI & Data Science Showcase:
Healx

Healx combines frontier AI technology with deep drug discovery and development expertise to accelerate the pace, increase the scale and improve the chance of success of rare disease treatment development.

Pioneering the Next Generation of Drug Discovery for Rare Disease
Hear how Healx are developing a new approach to drug discovery for rare diseases.

 Speaker Profile

Head of North America, QUIBIM

Biography
Mark Wittenberg is an entrepreneur in medical image processing and the application of AI methods to radiology. He has deep experience in the lab-to-market translation of AI models covering unmet clinical needs in oncology. He has worked to enable new AI technologies for research and clinical use at institutions such as Mass General Hospital, Mayo Clinic, and Duke. He earned his MBA at UCLA, and BA in Economics at Wesleyan University.


AI and Data Sciences Showcase:
QUIBIM

QUIBIM provides an AI platform focused on converting medical images into meaningful data. The company has a portfolio of accurate quantitative imaging solutions across oncology disease areas.

AI and Medical Imaging for Innovation in COVID-19
Imaging AI to optimize clinical and research outcomes.

 Speaker Profile

Ph.D., CEO, Co-Founder, OneThree Biotech

Biography
Prior to founding OneThree, Dr. Madhukar obtained his PhD from Weill Cornell, where his research focused on designing new machine learning architectures for drug discovery. During this time he authored 40+ scientific publications in the fields of machine learning, drug discovery, and precision medicine. His work has led to the development of new AI prediction methods, the discovery of a novel class of cancer therapeutics, and the start of new clinical trials. Dr. Madhukar is an awardee of the PhRMA informatics fellowship, was named one of Forbes “30 under 30” in Healthcare, and was named as one of the top 100 AI Leaders in Drug Discovery and Advanced Healthcare by Deep Knowledge Analytics.


AI and Data Sciences Showcase:
OneThree Biotech

OneThree Biotech has developed an AI platform to identify new therapeutic opportunities (e.g. novel cancer targets, genetic interactions, or disease mechanisms) that were missed by current techniques. From this they're building a pipeline of first-in-class cancer therapeutics

The ATLANTIS Platform for Novel Target Discovery
How the ATLANTIS platform accelerates the discovery and derisking of novel disease targets

 Speaker Profile

Ph.D., Chief Technology Officer (CTO), Pangea Biomed

Biography
Ranit is an AI researcher and expert with two decades of hands-on experience. She works to advance Pangea’s machine-learning tumor intelligence platform, enabling deeper understanding of how a tumor would respond to therapy. Prior to her role with Pangea, Ranit worked at IBM Research AI where her team developed Project Debater, the first AI system capable of debating humans on complex topics. In February 2019, the AI system won the Edison Award in Social Innovation – Artificial Intelligence. Ranit continued at IBM Research managing Natural Language Processing (NLP) teams before transitioning to become CTO of Pangea. For almost a decade before joining IBM, Ranit served as the Vice President of R&D at Rosetta Genomics (NASDAQ: ROSG). Rosetta Genomics developed microRNA-based molecular diagnostics. The company won the Wall Street Journal Technology Innovation award in 2008 while Ranit led the R&D efforts, including directly supervising all computational biology, software development and IP.


AI and Data Science Showcase:
Pangea Biomed

Pangea Biomed created ENLIGHT, the world’s most advanced multi-cancer, multi-therapy response predictor. By combining machine learning and deep RNA analysis, the company analyzes tumor molecular signatures to uncover cancer vulnerabilities missed by standard molecular profiling, for effective personalized cancer care and accelerated drug development.

Using AI to Democratize Precision Oncology
How AI and RNA-sequencing advance the evolution and accessibility of precision oncology.

 Speaker Profile

Ph.D., COO/CSO, AMPEL BioSolutions

Biography
Dr. Grammer is an internationally recognized scientist and successful entrepreneur, having founded and managed AMPEL successfully for over 5 years. Dr. Grammer was elected to the class of 2021 for SIBF (Society of International Business Fellows), an organization of 1,400 individuals in 45 countries worldwide. She was also awarded a Virginia SBIG grant for AMPEL's first investment round. She is a second term board member of Virginia Bio.Before co-founding AMPEL in 2013, Dr. Grammer spent over 20+ years in genomics and managed more than 15 National Institute of Health (NIH) scientific teams and a highly productive NIH laboratory. Dr. Grammer received multiple awards for her team's work comparing genes expressed in patients compared with healthy individuals, including the prestigious NIH Director's Award as well as mentoring awards from the American Association of Immunologists. She has published over 75 articles on her scientific research.


AI and Data Sciences Showcase:
AMPEL BioSolutions

AMPEL is a precision medicine company with a development pipeline of CLIA-certified gene expression tests for blood or tissue samples that determine disease status, identify molecular pathway and predict best drugs. Genomic platform, bioinformatics, RNA analytics and ML/AI algorithms covered by patents & are disease agnostic.

LuGENE Px for Lupus
AMPEL’s LuGENE® Px blood test evaluates Lupus disease status, identifies molecular pathways and predicts drug options. Filed patents protect AMPEL’s genomic platform, bioinformatics, RNA analytics and machine learning algorithms as well as disease specific applications in oncology, autoimmunity and infectious disease.

 Speaker Profile

M.D., Head of Pathology, Nucleai

Biography
Kenneth J Bloom, MD, FCAP is the Head of Pathology at Nucleai. He brings more than 35 years of clinical experience in pathology, oncology, telemedicine, and bioinformatics. Dr. Bloom has held a myriad of leadership positions including President and Head of Oncology & Immunotherapy for Human Longevity Inc., Chief Medical Officer for In Vitro Diagnostics at GE Healthcare, and Chief Medical Officer of Clarient. Prior to his industry experience, Dr. Bloom spent 15 years at Rush Medical Center holding various appointed positions including Director of Laboratory Operations, Director of Immunohistochemistry and Chief Information Officer of the Rush Cancer Institute. Dr. Bloom has been the principle investigator of more than a dozen clinical trials and has served as an advisor to numerous Pharmaceutical and Bio-Technology Companies. He received M.D. from Rush Medical College and his B.A. from Grinnell College.


AI and Data Science Showcase:
Nucleai

Nucleai is an AI-powered spatial biology company with a mission to transform drug development and clinical treatment decisions by unlocking and analyzing the valuable information in the pathology data.

AI driven spatial biology, the next NGS
AI driven spatial biology will revolutionize our understating of tumor biology.

 Speaker Profile

Ph.D., computational biologist professor , Weizmann Inst. of Science

Biography
Eran Segal heads a multi-disciplinary team of computational biologists and experimental scientists in Computational and Systems biology. His research focuses on Microbiome, Nutrition, Genetics, and their effect on health and disease. His aim is to develop personalized medicine based on big data from human cohorts. Prof. Segal published over 200 publications, and received several awards and honors for his work. During the COVID-19 pandemic, Prof. Segal developed models for analyzing the dynamics of the pandemic and served as an advisor to the government of Israel. Before joining the Weizmann Institute, Prof. Segal held an independent research position at Rockefeller University, New York. Education: Prof. Segal was awarded a B.Sc. in Computer Science summa cum laude in 1998, from Tel-Aviv University, and a Ph.D. in Computer Science and Genetics in 2004, from Stanford University


AI and Data Science Showcase:
Weizmann Inst. of Science

Pheno.AI manages The Human Phenotype Project with a mission to make accessible the world’s largest collection of deep-phenotype multi-omics datasets to improve human health. We do so by collecting and enabling others to collect, organize, analyze and make accessible these datasets

Personalized medicine based on deep human phenotyping
The technological and procedural building blocks, pitfalls and lessons learnt of building a deep phenotyped, multi-omics cohort

 Speaker Profile

CEO, BeanStock Ventures

Biography
Shawnnah Monterrey founded BeanStock Ventures following nearly a 20-year career as a technical leader. Shawnnah was responsible for developing strategies and leading complex global product development programs and functional management of software and software quality assurance departments for both startup and mature organization with emphasis on the development of medical instruments, life science, diagnostics, clinical applications.


AI and Data Science Showcase:
BeanStock Ventures

BeanStock Ventures is an FDA-accredited review organization, which provides software development and regulatory compliance products and services to minimize complexity, reduce cost and time to market of innovative medical devices.

Software Platform Development: Benefits & Challenges
Examining the benefits and challenges associated with developing a software platform.

 Speaker Profile

Ph.D., Solution Director, Pharma and Research, BC Platforms

Biography
Anni is an expert of genetic research software and data management. Her main responsibilities at BC Platforms are science communications, translational research projects, and solution design. Before joining BC Platforms, Anni worked as a researcher at Neuroscience center, University of Helsinki. During her Phd she specialised in cross-disciplinary research projects, and acquired knowledge and skills in biochemistry and physiology. Anni holds a PhD in Animal Physiology, Molecular Neurobiology from Univeristy of Helsinki and a MsC in Biochemistry, Chemistry from University of Eastern Finland.


AI and Data Sciences Showcase:
BC Platforms

BC Platforms is a global leader in building data networks for the life sciences industry and provides versatile technology platforms for personalized medicine, accelerating the translation of innovations into clinical practice.

First Global federated learning network secured with FHE
A novel environment for leveraging federated healthcare data for purposes of complex population analytics and machine learning.

 Speaker Profile

CEO & Co-founder, DrugBank

Biography
Michael Wilson has over a decade of experience in bioinformatics and metabolomics research with a background in Biological and Computer Sciences. He has co-authored 19 scientific publications and one textbook, as well as participated in two international data exchange committees for bioinformatics data formats. As DrugBanks’s CEO and co-founder, Michael leads the strategic direction, operations, management, and business development teams. His guidance and vision keep the DrugBank team motivated and striving to deliver even more innovative products.


AI and Data Science Showcase:
DrugBank

DrugBank is the world’s first intelligent and comprehensive drug knowledge platform. With the help of artificial intelligence, our expert team authors, verifies, and structures all of the latest biomedical information so that it can be used to its fullest potential.

TBC
Coming soon

 Speaker Profile

VP of Life Science Solutions, Flywheel

Biography
Costas has over 20 years of experience in research, development, and delivery of scientific information systems in the medical device, clinical research, and pharmaceutical domains with an emphasis on biomedical imaging. Costas joined Flywheel from Genentech, where he led the development of the Roche Global Imaging Platform, based on FAIR principles, which enables at-scale image data storage, ingestion, curation, and analysis.


AI and Data Sciences Showcase:
Flywheel

Flywheel is the biomedical research data management platform powering healthcare innovation by accelerating collaboration, enabling machine learning, and streamlining data aggregation, curation and management. By leveraging cloud scalability and automating research workflows, Flywheel helps organizations scale research data and analysis, improve collaboration and accelerate discoveries.

Improving AI with Diverse Datasets and Innovative Collaboration Tools
Flywheel Exchange provides a new platform to facilitate collaborations between AI researchers, scientists, clinicians, and commercial organizations.

 Speaker Profile

M.D., Sr. Medical Director, Medidata

Biography
Elizabeth Lamont, MD, MS is Senior Medical Director for Integrated Evidence at Medidata AI. A physician scientist with more than 25 years in academic medicine, she is a medical oncologist and a health services researcher. She both led NIH-funded research labs initially at the University of Chicago and then Harvard Medical School which focused on the generalizability of therapies developed in clinical trial settings and cared for patients with cancer in both ambulatory and hospital settings. At Medidata AI, she serves as an expert in research methodology at the interface of clinical medicine, clinical trials, and technology and as a clinical subject matter expert.


AI and Data Sciences Showcase:
Medidata

Medidata AI serve 1,300 customers and partners worldwide and empower more than 150,000 certified users every day to create hope for millions of patients.

Methods to Accelerate Technical and Regulatory Success
Rigorous study of historic patient-level clinical trial data and real-world data may accelerate drug development.

 Speaker Profile

, Omics Data Automation

Biography
Before starting Omics Data Automation, Gans was the chief architect of several generations of multi-core Xeon processors (2001 – 2013) starting with the first multicore server which resulted in more than 92% server market share for Intel. Starting 2014, he focused on Genomics and Precision Medicine driven by “Big Data”. As Director of the Precision Medicine group at Intel, he led the “Collaborative Cancer Cloud” a federated cloud platform for cancer research, collaborating with OHSU (Oregon Health Science University, OR), Broad Institute, [email protected] and various Cancer medical centers including Dana Farber Cancer Institute in Boston and OICR (Ontario Institute for Cancer Research) in Toronto. He also led Heterogeneous computing group and three Intel collaborations with academic centers at UC Berkeley, Technion Israel and UCLA in this area.


AI and Data Sciences Showcase:
Omics Data Automation

 Speaker Profile

Ph.D., SVP, General Manager, Seven Bridges

Biography
Jack leads the Scientific Center of Excellence, with focus on sustainable innovation, developing interoperability standards, democratizing access to research data, scientific leadership, and ultimately advancing the potential of genomics and health data to improve health. His team has developed advanced research ecosystems to help diverse stakeholders realize return on the investments that they have made in data generation and analysis environments. Jack serves as PI or co-I on multiple large projects and co-chairs the NIH Cloud Platform Interoperability Effort to help researchers bring together data and tools from NCI, NHLBI, Common Fund, NHGRI, and others. Jack’s training spans engineering and neuroscience; his academic research area was machine learning applied to sensory (vestibular) and motor (locomotion, reaching) neuroprosthetics.


AI and Data Sciences Showcase:
Seven Bridges

Seven Bridges is the industry-leading unified bioinformatics solutions company accelerating precision medicine by enabling the understanding of biomedical data. Our platform, analytic tools, and services expertise are driving discovery and drug development at the world’s leading academic, biotechnology, government, hospitals, and pharmaceutical entities.

Powering Precision R&D
Opportunities and challenges of revealing insights from complex multidimensional data.

 Speaker Profile

Ph.D., Chief of Artificial Intelligence, Tempus

Biography
Dr. Martin Stumpe serves as the Chief of AI at Tempus, where he leads the development of AI algorithms from NGS and digital pathology to improve clinical context and decision-making for better patient care. Prior to Tempus, Dr. Stumpe founded and led the Cancer Pathology project at Google, which uses artificial intelligence to increase the accuracy in image-based cancer detection and grading. Earlier in his career, Dr. Stumpe was part of the Kepler team at NASA Ames Research Center; and before that, he was a postdoctoral researcher at Stanford University focusing on molecular dynamics simulations to study chaperone-induced protein folding. Dr. Stumpe holds a PhD in Computational and Theoretical Physics from the Max Planck Institute for Biophysical Chemistry in Goettingen, Germany.


AI and Data Sciences Showcase:
Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, Tempus enables physicians to deliver personalized patient care and accelerates the development of optimal therapeutics.

Actionable AI: Data-Centric Decision-Making in Clinical Research
Impact of multimodal AI algorithms on patient diagnosis, prognosis, and clinical trial matching